Tech medical breakthrough

SynCardia Total Artificial Heart Bridges Patient to Transplant

Analysis based on 11 articles · First reported Feb 12, 2026 · Last updated Mar 19, 2026

Sentiment

Attention

Articles

Market Impact

Direct

Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard

Market Impact

The successful case involving the SynCardia Total Artificial Heart is positive for Picard Medical and Picard Medical===SynCardia Systems, potentially increasing investor confidence and market adoption of their medical device. This highlights the growing demand for advanced mechanical circulatory support in the healthcare market.

Medical Devices Healthcare

Event Summary

Picard Medical, Inc. highlighted a successful case at UCSF Health where a patient with advanced biventricular heart failure was bridged to heart transplantation using the SynCardia Total Artificial Heart. The patient received the device on November 15, 2025, and underwent a successful heart transplant on March 14, 2026, after 119 days of support. This marks the second successful transplantation at UCSF Health using the SynCardia Total Artificial Heart, underscoring the device's effectiveness and the growing experience with total artificial heart therapy at leading transplant centers. Amy G. Fiedler, MD, from UCSF Health, and Patrick N. J. Schnegelsberg, CEO of Picard Medical, both expressed satisfaction with the outcome and the partnership.

Key Actions

90 Picard Medical===SynCardia Systems provided critical circulatory support

80 Picard Medical highlighted successful patient case

70 UCSF Health successfully performed heart transplant

Entities Involved

subs

Picard Medical===SynCardia Systems

Picard Medical===SynCardia Systems, the developer and manufacturer of the SynCardia Total Artificial Heart, sees its product successfully bridge a patient to heart transplantation, reinforcing its position as a leader in artificial heart technology and potentially increasing its market adoption.

Importance 95 Sentiment 60

stock

Picard Medical

Picard Medical, as the parent company of Picard Medical===SynCardia Systems, benefits from the successful use of the SynCardia Total Artificial Heart, which highlights the effectiveness and growing adoption of its technology in critical medical procedures.

Importance 90 Sentiment 50

priv

UCSF Health

UCSF Health successfully performed a heart transplant after using the SynCardia Total Artificial Heart, demonstrating its expertise in advanced cardiac care and its partnership with Picard Medical===SynCardia Systems.

Importance 70 Sentiment 30

per

Amy G. Fiedler

Amy G. Fiedler, as a key surgeon at UCSF Health, successfully performed the redo sternotomy, total artificial heart explant, and heart transplant, contributing to the positive outcome of the case.

Importance 40 Sentiment 20

per

Patrick N. J. Schnegelsberg

Patrick N. J. Schnegelsberg, CEO of Picard Medical, expressed pride in the SynCardia Total Artificial Heart's role in the successful patient outcome, highlighting the growing need for advanced mechanical circulatory support.

Importance 30 Sentiment 10

govactor

United States===Food and Drug Administration

The United States===Food and Drug Administration's approval of the SynCardia Total Artificial Heart is mentioned, indicating its regulatory endorsement of the device.

Importance 10 Sentiment 0

govactor

Canada===Health Canada

Canada===Health Canada's approval of the SynCardia Total Artificial Heart is mentioned, indicating its regulatory endorsement of the device in Canada.

Importance 10 Sentiment 0

Relationships

Picard Medical related ↔ Picard Medical===SynCardia Systems

UCSF Health related ↔ Picard Medical===SynCardia Systems

Patrick N. J. Schnegelsberg related ↔ Picard Medical

Picard Medical related ↔ UCSF Health

NEWSDESK

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard